Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 10/20 | 0.62 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.58 |
| ▸ | GABRP | O00591 | 1/20 | 0.47 |
| ▸ | GABRD | O14764 | 1/20 | 0.47 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.47 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.47 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.47 |
| ▸ | GABRE | P78334 | 1/20 | 0.47 |
| ▸ | GABRA6 | Q16445 | 1/20 | 0.47 |
| ▸ | GABRG1 | Q8N1C3 | 1/20 | 0.47 |
| ▸ | GABRG3 | Q99928 | 1/20 | 0.47 |
| ▸ | GABRQ | Q9UN88 | 1/20 | 0.47 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6719735 | 0.87 | ADORA3 (0.59) | ADORA3ADORA1ADORA2AGABRPGABRD | |
| SCHEMBL6715654 | 0.81 | ADORA3 (0.65) | ADORA3ADORA1ADORA2A | |
| SCHEMBL6715666 | 0.77 | ADORA3 (0.69) | ADORA3ADORA1ADORA2A | |
| SCHEMBL6716513 | 0.76 | ADORA3 (0.65) | ADORA3ADORA1ADORA2A | |
| SCHEMBL6715589 | 0.76 | ADORA3 (0.66) | ADORA3ADORA1ADORA2A | |
| SCHEMBL25516147 | 0.72 | ADORA3 (0.88) | ADORA3ADORA1ADORA2AGABRPGABRD | |
| SCHEMBL6715662 | 0.72 | ADORA3 (0.58) | ADORA3ADORA1ADORA2A | |
| SCHEMBL6720118 | 0.72 | ADORA3 (0.52) | ADORA3ADORA1ADORA2A | |
| SCHEMBL24840150 | 0.69 | ADORA3 (0.81) | ADORA3ADORA1PDPK1MAPTMEN1 | |
| SCHEMBL6715427 | 0.69 | ADORA3 (0.53) | ADORA3ADORA1ADORA2AXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142952-A1 | Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2004-07-22 | — | — | US | disclosed |
| EP-1364953-A1 | TRIAZOLOQUINAZOLINE AND PYRAZOLOTRIAZOLOPYRIMIDINE DERIVATIVES, MEDICINAL COMPOSITIONS, ADENOSINE A3 RECEPTOR AFFINITY AGENTS, OCULAR TENSION LOWERING AGENTS, PREPARATIONS FOR PREVENTING AND TREATING GLAUCOMA AND METHOD OF LOWERING OCULAR TENSION | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 2003-11-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142952-A1 | Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension | ADORA3, ADORA1, ADORA2A | ADORA3 1/4885ADORA1 2/4885ADORA2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.